MedTrace Logo

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

NCT06029257 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-01-29

No results posted yet for this study

Summary

The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.

Conditions

  • Genital Psoriasis

Interventions

DRUG

Tildrakizumab

As provided in real-world clinical practice.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029257 on ClinicalTrials.gov